Christopher J Patterson Selected Research

Waldenstrom Macroglobulinemia (Macroglobulinemia)

1/2022	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
1/2022	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
1/2022	Venetoclax in Previously Treated Waldenström Macroglobulinemia.
1/2022	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
11/2021	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
10/2021	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
1/2021	Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia.
1/2021	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
6/2020	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials.
1/2020	CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher J Patterson Research Topics

Disease

52	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 03/2005
12	Lymphoma (Lymphomas) 01/2022 - 01/2007
12	Neoplasms (Cancer) 11/2021 - 08/2007
5	Bone Marrow Diseases (Bone Marrow Disease) 10/2021 - 08/2009
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 02/2011
4	Disease Progression 01/2018 - 03/2010
4	Heart Failure 01/2018 - 08/2004
4	Paraproteinemias (Monoclonal Gammopathy) 03/2013 - 08/2007
3	Cardiac Arrhythmias (Arrythmia) 01/2021 - 03/2005
3	Multiple Myeloma 01/2018 - 08/2012
3	Atrial Fibrillation 04/2015 - 08/2004
3	Peripheral Nervous System Diseases (PNS Diseases) 07/2014 - 12/2008
3	Anemia 04/2013 - 01/2009
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 01/2016
2	Cardiomyopathies (Cardiomyopathy) 01/2018 - 07/2014
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2016 - 03/2013
2	Neutropenia 04/2015 - 07/2014
2	Splenomegaly 03/2010 - 03/2005
2	Lymphadenopathy 03/2010 - 03/2005
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2009 - 01/2009
1	Thrombocytopenia (Thrombopenia) 04/2015
1	Epistaxis (Nosebleed) 04/2015
1	Hemorrhage 04/2015
1	Iron Deficiencies 04/2013
1	Monoclonal Gammopathy of Undetermined Significance 03/2013
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 07/2011
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2011
1	Hematologic Neoplasms (Hematological Malignancy) 02/2011
1	Reinfection 03/2010
1	Agammaglobulinemia (Hypogammaglobulinemia) 03/2010
1	Herpes Zoster 08/2009
1	Fever (Fevers) 03/2009
1	Leukemia 01/2009
1	Cytopenia 01/2009
1	Hemolysis 01/2009
1	type 2C Congenital disorder of glycosylation 12/2008

Drug/Important Bio-Agent (IBA)

19	Immunoglobulin M (IgM)IBA 10/2021 - 08/2007
13	ibrutinibIBA 01/2022 - 04/2015
13	Rituximab (Mabthera)FDA Link 01/2020 - 01/2007
4	Bortezomib (Velcade)FDA Link 07/2014 - 08/2007
4	Immunoglobulin G (IgG)IBA 07/2014 - 01/2007
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 08/2013
3	Hemoglobins (Hemoglobin)IBA 10/2021 - 05/2017
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2007
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 08/2009
3	Immunoglobulin A (IgA)IBA 07/2014 - 03/2005
3	Immunoglobulins (Immunoglobulin)IBA 04/2013 - 01/2007
3	Monoclonal AntibodiesIBA 07/2011 - 01/2007
2	venetoclaxIBA 01/2022 - 11/2021
2	ResveratrolIBA 08/2019 - 03/2008
2	IronIBA 04/2013 - 02/2011
2	HepcidinsIBA 04/2013 - 02/2011
2	Thalidomide (Thalomid)FDA Link 12/2008 - 08/2007
2	Digoxin (Digitek)FDA LinkGeneric 03/2005 - 08/2004
1	src-Family KinasesIBA 01/2022
1	A 419259IBA 01/2022
1	ulocuplumabIBA 10/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2020
1	Proteasome InhibitorsIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2020
1	ChromatinIBA 01/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	ixazomibIBA 01/2020
1	Proto-Oncogene Proteins c-hckIBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2018
1	Thiamine (Aneurin)FDA Link 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	pro-brain natriuretic peptide (1-76)IBA 01/2018
1	Everolimus FDA Link 05/2017
1	Fish OilsIBA 04/2015
1	carfilzomibIBA 07/2014
1	Myeloid Differentiation Factor 88IBA 08/2013
1	Transferrin (beta 2 Transferrin)IBA 04/2013
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2011
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2011
1	p38 Mitogen-Activated Protein KinasesIBA 09/2011
1	Vorinostat FDA Link 09/2011
1	Alemtuzumab (Campath)FDA Link 07/2011
1	Bendamustine Hydrochloride FDA Link 02/2011
1	Matrix Metalloproteinase 8 (Neutrophil Collagenase)IBA 02/2011
1	Metalloproteases (Metalloproteinases)IBA 02/2011
1	Histone Deacetylase InhibitorsIBA 02/2011
1	Antiviral Agents (Antivirals)IBA 08/2009
1	fludarabineIBA 04/2009
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2009
1	Vincristine (Oncovin)FDA LinkGeneric 03/2009
1	nasIBA 01/2009
1	NucleosidesIBA 01/2009
1	Lenalidomide (CC 5013)FDA Link 01/2009
1	CD40 Ligand (CD40L)IBA 12/2008

Therapy/Procedure

19	Therapeutics 01/2021 - 12/2006
3	Long-Term Care 12/2006 - 08/2004
1	Oral Administration 11/2021
1	Aftercare (After-Treatment) 04/2013
1	Cardiopulmonary Resuscitation (CPR) 03/2009
1	Plasmapheresis 03/2009